Evaluation of the Relationship Between Cognitive Impairment, Glycometabolism, and Nicotinic Acetylcholine Receptor Deficits in a Mouse Model of Alzheimer’s Disease

[1] McKhann GM(2011)The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease Alzheimers Dement 7 263-269

[2] Knopman DS(2008)Screening for dementia in primary care: a review of the use, efficacy and quality of measures Int Psychogeriatr 20 911-926

[3] Chertkow H(2015)Imaging biomarkers associated with cognitive decline: a review Biol Psychiatry 77 685-692

[4] Milne A(1998)Age at onset and regional cerebral glucose metabolism in Alzheimer’s disease Dement Geriatr Cogn Disord 9 63-67

[5] Culverwell A(1998)Nicotinic acetylcholine involvement in cognitive function in animals Psychopharmacol 138 217-230

[6] Guss R(2001)Nicotinic acetylcholine receptor alpha 7 and alpha 4 beta 2 subtypes differentially control GABAergic input to CA1 neurons in rat hippocampus J Neurophysiol 86 3043-3055

[7] Tuppen J(2001)Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer’s disease Biol Psychiatry 49 279-288

[8] Whelton R(2010)Mechanisms of neuroprotective effects of nicotine and acetylcholinesterase inhibitors: role of alpha 4 and alpha 7 receptors in neuroprotection J Mol Neurosci 40 211-216

[9] McConathy J(1998)Stimulation of alpha 4 beta 2 nicotinic acetylcholine receptors inhibits beta-amyloid toxicity Brain Res 792 331-334

[10] Sheline YI(2002)Evaluation of radioiodinated 5-iodo-3-(2(S)-azetidinylmethoxy)pyridine as a ligand for SPECT investigations of brain nicotinic acetylcholine receptors Ann Nucl Med 16 189-200

[1] McKhann GM(2011)The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease Alzheimers Dement 7 263-269

[2] Knopman DS(2008)Screening for dementia in primary care: a review of the use, efficacy and quality of measures Int Psychogeriatr 20 911-926

[3] Chertkow H(2015)Imaging biomarkers associated with cognitive decline: a review Biol Psychiatry 77 685-692

[4] Milne A(1998)Age at onset and regional cerebral glucose metabolism in Alzheimer’s disease Dement Geriatr Cogn Disord 9 63-67

[5] Culverwell A(1998)Nicotinic acetylcholine involvement in cognitive function in animals Psychopharmacol 138 217-230

[6] Guss R(2001)Nicotinic acetylcholine receptor alpha 7 and alpha 4 beta 2 subtypes differentially control GABAergic input to CA1 neurons in rat hippocampus J Neurophysiol 86 3043-3055

[7] Tuppen J(2001)Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer’s disease Biol Psychiatry 49 279-288

[8] Whelton R(2010)Mechanisms of neuroprotective effects of nicotine and acetylcholinesterase inhibitors: role of alpha 4 and alpha 7 receptors in neuroprotection J Mol Neurosci 40 211-216

[9] McConathy J(1998)Stimulation of alpha 4 beta 2 nicotinic acetylcholine receptors inhibits beta-amyloid toxicity Brain Res 792 331-334

[10] Sheline YI(2002)Evaluation of radioiodinated 5-iodo-3-(2(S)-azetidinylmethoxy)pyridine as a ligand for SPECT investigations of brain nicotinic acetylcholine receptors Ann Nucl Med 16 189-200